StockData

Enanta Pharmaceuticals vs SIGA Technologies

ENTA and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ENTA and SIGA compare

Enanta Pharmaceuticals is the larger company, worth 1.5 times as much as SIGA Technologies ($311M against $205M).

SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of −5.2% compared with −96.9% at Enanta Pharmaceuticals.

SIGA Technologies pays a dividend yielding 21.1%; Enanta Pharmaceuticals does not pay one.

SIGA Technologies scores higher on the StockData Score (14 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricENTASIGA
Size and price
Market cap$311M$205M
Share price$10.67$2.85
Change, 1 year−9.0%−53.1%
Change, 5 years−88.4%−66.6%
Beta (5Y)1.470.43
Employees12049
StockData Score
Total score214 (better)
Valuation score03 (better)
Growth score00
Performance score12 (better)
Health score16 (better)
Dividend score03 (better)
Valuation
P/S4.8×3.8× (better)
P/B3.1×1.2× (better)
FCF yield−11.9%–
Fair value$9.66$7.42
Margin of safety−10.5%61.6% (better)
Growth
Revenue growth (TTM)–−70.1%
Revenue growth, 5Y average−11.8%−5.4% (better)
Net income growth (TTM)–−103%
EPS growth (TTM)–−104%
EPS growth, 5Y average–−14.7%
Profitability
Gross margin–54.4%
Operating margin−90.0%−20.8% (better)
Net margin−96.9%−5.2% (better)
FCF margin−56.6%–
Return on equity−70.1%−1.5% (better)
Return on invested capital–−23.6%
Financial health
Debt / equity–0.00
Interest coverage−4.5×–
Current ratio3.7621.72 (better)
Altman Z-score−1.0012.35 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Dividend yield–21.1%
Years of dividend growth–0
Shareholder yield0.00%21.1% (better)
Ownership
Held by institutions93.6%48.5%
Held by insiders7.9%1.9%
Insider net buying, 12 months−$183K–
Short interest, % of float6.9%5.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.